Abstract
Direct acting antiviral therapies (DAAs), are currently the state of the art therapy of chronic Hepatitis C (CHC) giving hope particularly to patients with liver cirrhosis. The aim of the study was to investigate the ability to use baseline data as predictors of non-response to DAAs in patients with CHC.
Highlights
Chronic hepatitis C (CHC) is considered a major etiology of chronic hepatitis and cirrhosis around the world in Egypt [1,2]
Egypt previously had the highest Hepatitis C virus (HCV) burden worldwide as reported in 2008, with 90% of patients infected with genotype-4 [3,4]
This study aims to investigate the relation between baseline AFP and the response to treatment in 2446 chronic HCV patients treated with Direct acting antiviral therapies (DAAs) using routine pretreatment workup
Summary
Chronic hepatitis C (CHC) is considered a major etiology of chronic hepatitis and cirrhosis around the world in Egypt [1,2]. Egypt previously had the highest Hepatitis C virus (HCV) burden worldwide as reported in 2008, with 90% of patients infected with genotype-4 [3,4]. Serum alpha-fetoprotein (AFP) is a fetal glycoprotein secreted by the yolk sac and liver of the fetus [7]. Direct acting antiviral therapies (DAAs), are currently the state of the art therapy of chronic Hepatitis C (CHC) giving hope to patients with liver cirrhosis.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
